🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Essen
Clinical trial register · Germany

Clinical Trials in Essen, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Germany and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5051 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:51 UTC
5051
Studies in scope
all four open statuses
2882
Recruiting now
open to new participants
988
Lead sponsors
across recruiting studies
Top sites
Berlin 1584 Hamburg 889 Essen 760 Dresden 707 Heidelberg 627
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca57 Novartis Pharmaceuticals50 Eli Lilly and Company30 Amgen27 University Hospital, Essen27
Site location
Berlin1584 Hamburg889 Essen760 Dresden707 Heidelberg627
All 635 locations
Target enrolment
to

Trials with a site in Essen

760 of 5051 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Germany
Start
Recruiting
Rescue of Nephrons With ALE.F02 (RENAL-F02)
NCT06047171Glomerulonephritis Rapidly Progressive
DrugsCyclophosphamid·Rituximab
Alentis Therapeutics AG
Phase 2
80
Berlin, Cologne, Dresden, Essen, Hanover, Leipzig, Lübeck, München
2023-09-07
Recruiting
The ReTAVI Prospective Observational Registry
NCT05601453Structural Valve Deterioration, Structural Valve Degeneration, Symptomatic Patients Who Have Had Transcatheter Heart Valve (THV) Failure, Prosthetic Valve Malfunction
Institut für Pharmakologie und Präventive Medizin
Observational
250
Bad Krozingen, Bad Nauheim, Bad Oeynhausen, Berlin, Bochum, Düsseldorf, Essen, Munich
2023-09-05
Not yet open
SURgical Registry of ENDocarditis EuRope
NCT05563662Infective Endocarditis, Cardiac Surgery, Outcomes
University Hospital, Essen
Observational
10,000
Nuremberg, Essen
2023-09
Active, closed
A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations
NCT06052267Asthma
Teva Branded Pharmaceutical Products R&D LLC
Phase 3
2,772
Augsburg, Berlin, Cottbus, Darmstadt, Delitzsch, Essen, Frankfurt, Frankfurt am Main
2023-08-30
Active, closed
Organ Preservation With Durvalumab-based Immunotherapy in Combination With Chemoradiation as Definitive Therapy for Early Stage Esophageal Adenocarcinoma With Indication for Radical Surgery
NCT05713838Esophagus Adenocarcinoma
DrugsFLOT·MFOLFOX6·Durvalumab
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2
32
Amberg, Bad Saarow, Berlin, Brandenburg an der Havel, Bremen, Darmstadt, Essen, Frankfurt
2023-08-28
Recruiting
Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
NCT05803941Prostate Cancer
DrugLu-PSMA
Novartis Pharmaceuticals
Phase 4
700
Essen, München, Rostock
2023-08-14
By invitation
Evaluation of Long-Term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor in Cystic Fibrosis Participants 1 Year of Age and Older
NCT05844449Cystic Fibrosis
DrugVNZ/TEZ/D-IVA
Vertex Pharmaceuticals Incorporated
Phase 3
174
Berlin, Essen, Hanover
2023-08-11
Active, closed
A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
NCT05933577Melanoma
DrugsIntismeran autogene·Keytruda·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
1,089
Mannheim, Augsburg, München, Göttingen, Rostock, Cologne, Essen, Minden
2023-07-19
Active, closed
A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer
NCT05852691Breast Cancer
DrugsTobemstomig·Nab-paclitaxel·Pembrolizumab
Hoffmann-La Roche
Phase 2
83
Essen, Langen, Ulm
2023-07-18
Recruiting
The LYMPH Trial - Microsurgical Versus Conservative Treatment of Chronic Breast Cancer Associated Lymphedema
NCT05890677Lymphedema, Breast Cancer
University Hospital, Basel, Switzerland
Not applicable
280
Bochum, Düsseldorf, Erlangen, Essen, Frankfurt, Freiburg im Breisgau, Ludwigshafen am Rhein, Nuremberg
2023-07-14
Active, closed
A Study of Zigakibart in Adults With IgA Nephropathy
NCT05852938IgA Nephropathy, Immunoglobulin A Nephropathy
DrugZigakibart
Novartis Pharmaceuticals
Phase 3
383
Augsburg, Hanover, Mainz, Trier, Magdeburg, Jena, Essen
2023-07-06
Active, closed
ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors
NCT05671510Non Small Cell Lung Cancer
DrugsGotistobart·Taxotere·Docetaxel
OncoC4, Inc.
Phase 3
630
Bogenhausen, Essen, Esslingen am Neckar, Immenhausen, Immenstädt, Muenchen-Gauting
2023-06-28
Active, closed
A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
NCT05878769Chronic Obstructive Pulmonary Disease
DrugAstegolimab
Hoffmann-La Roche
Phase 3
2,000
Augsburg, Bamberg, Bendorf, Berlin, Darmstadt, Deggingen, Essen, Frankfurt
2023-06-28
Active, closed
Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.
NCT05838768MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers
DrugsIrinotecan·Pembrolizumab
Novartis Pharmaceuticals
Phase 1
123
Essen
2023-06-27
Active, closed
A Real World Effectiveness Study of Pegcetacoplan in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT05776472Paroxysmal Nocturnal Hemoglobinuria
DrugPegcetacoplan
Swedish Orphan Biovitrum
Observational
165
Goettigen, Aschaffenburg, Frankfurt am Main, Giessen, Offenbach, Essen, Leipzig, Saalfeld
2023-06-26
Recruiting
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
NCT05646862Breast Cancer
DrugsBupropion·Omeprazole·Alpelisib·Inavolisib
Hoffmann-La Roche
Phase 3
420
Aachen, Bielefeld, Essen, Freiburg im Breisgau, Georgsmarienhütte, Göttingen, Hamburg, Hanover
2023-06-07
Recruiting
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
NCT05797168Ovarian Cancer, Lung Adenocarcinoma, Endometrial Cancer, Lung Squamous Cell Carcinoma
DrugsTorvutatug samrotecan·Palacaparib·Saruparib·Paraplatin
AstraZeneca
Phase 1/2
602
Berlin, Essen, Freiburg im Breisgau, Hanover, Leipzig, Mannheim, Regensburg
2023-06-05
Active, closed
A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)
NCT05881408Duchenne Muscular Dystrophy
Sarepta Therapeutics, Inc.
Phase 3
148
München, Essen, Hamburg
2023-05-31
Active, closed
Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer
NCT05740566Small Cell Lung Cancer (SCLC)
DrugsAmrubicin·Lurbinectedin·Tarlatamab·Topotecan
Amgen
Phase 3
509
Berlin, Cologne, Dresden, Essen, Gauting, Großhansdorf, Stuttgart, Würzburg
2023-05-31
Active, closed
NeoTRACK - Dissection of IO Efficacy in NSCLC by Longitudinal tracKing
NCT05825625Non-small Cell Lung Cancer
DrugsTiragolumab·Tecentriq·Atezolizumab
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2
35
Essen, Heidelberg
2023-05-26
Recruiting
A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL
NCT05748171ACUTE LYMPHOBLASTIC LEUKEMIA
DrugInotuzumab Ozogamicin
Pfizer
Phase 2
100
Freiburg im Breisgau, Ulm, Würzburg, Frankfurt am Main, Hanover, Essen, Münster, Kiel
2023-05-17
Active, closed
Immunogenicity of COVID-19 Vaccination in Immunocompromised Patients (Auto-COVID-VACC)
NCT05597761COVID-19, Adult, Immunocompromised Patients
Oliver Cornely, MD
Observational
49
Aachen, Cologne, Essen
2023-05-15
Recruiting
Prognostic Potential of Olfactory Function in Glioblastoma: a Prospective Observational Study
NCT06954636Glioblastoma Multiforme, Adult, Glioblastoma or Gliosarcoma, Glioblastoma, Adult
Sied Kebir
Observational
128
Essen, Münster
2023-05-03
Active, closed
IMPACT EU Post-Market Clinical Follow-Up Study
NCT05756751Left Ventricular Dysfunction
Abiomed Inc.
Not applicable
123
Heidelberg, Aachen, Düsseldorf, Essen, Mainz, Halle, Kiel, Berlin
2023-04-27
Recruiting
Impact of Stress on Cardiovascular Events in Patients with Peripheral Arterial Disease
NCT06887101Peripheral Arterial Disease
University Hospital, Essen
Observational
300
Essen
2023-04-21
Active, closed
Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab
NCT05626855Spinal Muscular Atrophy, Spinal Muscular Atrophy Type 3, Spinal Muscular Atrophy Type 2, SMA
DrugApitegromab
Scholar Rock, Inc.
Phase 3
238
Bonn, Essen, Freiburg im Breisgau, Munchen, Bayern
2023-04-17
Recruiting
Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women
NCT04124120Heart Diseases, Coronary Artery Disease, Coronary Artery Bypass Grafting
Weill Medical College of Cornell University
Not applicable
2,300
Bad Krozingen, Bad Oeynhausen, Berlin, Duisburg, Düsseldorf, Erlangen, Essen, Frankfurt
2023-04-17
Active, closed
A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)
NCT05714202Bladder Cancer
DrugsTAR-200·Cetrelimab
Janssen Research & Development, LLC
Phase 3
1,135
Cologne, Duisburg, Erlangen, Essen, Frankfurt am Main, Freiburg im Breisgau, Markkleeberg, Mettmann
2023-03-23
Recruiting
Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-NOW and 2021 WHO Classification
NCT05259605Glioma, Glioneuronal Tumor, Choroid Plexus Tumor, Pineal Tumors
European Organisation for Research and Treatment of Cancer - EORTC
Observational
1,650
Bochum, Bonn, Cologne, Essen, Frankfurt, Jena, Leipzig, Regensburg
2023-03-21
Active, closed
Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP
NCT05798156Lymphoma, Large B-Cell, Diffuse
DrugsPolatuzumab Vedotin·Glofitamab·Obinutuzumab·Rituximab
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2
125
Magdeburg, Berlin, Bochum, Chemnitz, Düsseldorf, Erlangen, Essen, Halle
2023-03-20
Recruiting
Tafasitamab (MOR00208) in Pediatric Patients With Relapsed or Refractory Acute B Lineage Leukemia
NCT05366218ALL, Childhood B-Cell, Acute Lymphoid Leukemia Relapse, Acute Lymphocytic Leukemia Refractory
DrugTafasitamab
University Hospital Tuebingen
Phase 1/2
20
Freiburg im Breisgau, Tübingen, Ulm, München, Hamburg, Düsseldorf, Berlin, Essen
2023-03-08
Active, closed
REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels
NCT05669755Cardiovascular Disease
DrugsCagrilintide·Semaglutide
Novo Nordisk A/S
Phase 3
7,101
Dortmund, Dresden, Elsterwerda, Essen, Frankfurt, Hamburg, Heidelberg, Leipzig
2023-03-01
Active, closed
DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)
NCT05566795Low-grade Glioma, Rapidly Accelerated Fibrosarcoma (RAF) Altered Glioma, Pediatric Low-grade Glioma
DrugTovorafenib
Day One Biopharmaceuticals, Inc.
Phase 3
418
Freiburg im Breisgau, Augsburg, Erlangen, Würzburg, Frankfurt am Main, Hanover, Essen, Leipzig
2023-02-27
Active, closed
A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)
NCT05668741Cystic Fibrosis
DrugIvacaftor
Vertex Pharmaceuticals Incorporated
Phase 1/2
26
Essen
2023-02-27
Recruiting
Improving Adherence to Statin Therapy Through a Medication Management Application
NCT05777655Atherosclerosis
University Hospital, Essen
Not applicable
250
Essen
2023-02-17
Active, closed
A MultIceNTER Phase I Peptide VaCcine Trial for the Treatment of H3-Mutated Gliomas
NCT04808245Newly Diagnosed H3-mutated Glioma
DrugsTecentriq·Atezolizumab
German Cancer Research Center
Phase 1
15
Heidelberg, Mannheim, Tübingen, Frankfurt am Main, Bonn, Essen, Dresden, Berlin
2023-02-15
Active, closed
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
NCT05702034Ischemic Stroke; Ischemic Attack, Transient
DrugMilvexian
Janssen Research & Development, LLC
Phase 3
12,523
Aachen, Altenburg, Bad Neustadt an der Saale, Berlin, Dortmund, Dresden, Erlangen, Essen
2023-02-15
Recruiting
A Safety and Pharmacokinetics Trial of VO659 in SCA1, SCA3 and HD
NCT05822908Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 3, Huntington Disease
Vico Therapeutics B. V.
Phase 1/2
68
Bochum, Bonn, Essen, Tübingen
2023-02-14
Active, closed
Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)
NCT05653349Primary Immune Thrombocytopenia (ITP)
DrugIanalumab
Novartis Pharmaceuticals
Phase 3
226
Frankfurt am Main, Dresden, Jena, Essen, Giessen
2023-02-03
Active, closed
Post Market Clinical Follow-up of CODMAN CERTAS Programmable Valve
NCT05397106Hydrocephalus, Hydrocephalus in Children, NPH (Normal Pressure Hydrocephalus), IIH - Idiopathic Intracranial Hypertension
Integra LifeSciences Corporation
Observational
160
Dortmund, Düsseldorf, Essen, Freiburg im Breisgau, Stuttgart
2023-01-24
Recruiting
ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)
NCT05580562H3 K27M, Glioma
DrugDordaviprone
Jazz Pharmaceuticals
Phase 3
510
Heidelberg, Augsburg, Regensburg, Frankfurt am Main, Bonn, Cologne, Essen, Berlin
2023-01-23
Active, closed
A Clinical Trial to Investigate the Long-term Safety and Tolerability, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of ARGX-117 in Adults With Multifocal Motor Neuropathy
NCT05405361Multifocal Motor Neuropathy (MMN)
DrugEmpasiprubart
argenx
Phase 2
51
Essen, Göttingen
2023-01-18
Active, closed
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
NCT05555732Metastatic Non Small Cell Lung Cancer
DrugsDatopotamab deruxtecan·Pemetrexed·Keytruda·Cisplatin
Daiichi Sankyo
Phase 3
1,170
Berlin, Chemnitz, Essen, Esslingen am Neckar, Freiburg im Breisgau, Giessen, Mannheim, Munich
2023-01-11
Recruiting
Endurant Stent Graft System vs Excluder Endoprothesis: ADVANCE Trial
NCT05378347Abdominal Aortic Aneurysm, Abdominal Aortic Aneurysm >= 5.5 Centimeters in Male (Disorder), Abdominal Aortic Aneurysm >= 5.0 Centimeters in Female (Disorder)
Medtronic Cardiovascular
Not applicable
600
Augsburg, Cologne, Essen, Frankfurt, Leipzig, Munich, Münster
2023-01-05
Recruiting
Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer
NCT05306041HER2-positive Breast Cancer
DrugsPhesgo·Inavolisib
GBG Forschungs GmbH
Phase 2
170
Essen, Augsburg, Berlin, Bielefeld, Chemnitz, Cologne, Dessau, Dresden
2023-01-02
Recruiting
Real-World Effects of MC4R Agonist Therapy in BBS and Severe Genetic Obesity
NCT07674290Bardet Biedl Syndrome (BBS), Bardet Biedl Syndrome, Bardet-Biedl Syndrome (BBS), Alstrom Syndrome
DrugSetmelanotide
Tom Hühne
Phase 4
200
Essen
2023-01-01
Active, closed
A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia
NCT05648968Warm Autoimmune Hemolytic Anemia (wAIHA)
DrugIanalumab
Novartis Pharmaceuticals
Phase 3
90
Dresden, Essen, Giessen, Hanover
2022-12-30
Recruiting
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
NCT05549297Advanced Melanoma
DrugTebentafusp
Immunocore Ltd
Phase 3
540
Schleswig, Berlin, Dresden, Erlangen, Essen, Hamburg, Heidelberg, Kiel
2022-12-19
Active, closed
Acute Immunological Effects of Exercise in Cancer Patients
NCT05656651Cancer
Universität Duisburg-Essen
Phase 2
60
Essen
2022-12-19
Recruiting
DERIVO® 2heal® Study: Clinical Safety and Efficacy of the DERIVO® 2heal® Embolisation Device
NCT05543447Intracranial Aneurysm, Flow Diverter
Acandis GmbH
Observational
158
Augsburg, Berlin, Bremerhaven, Cologne, Dresden, Düsseldorf, Essen, Frankfurt am Main
2022-12-15
Active, closed
Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial
NCT05581303Atherosclerotic Cardiovascular Disease
DrugOlpasiran
Amgen
Phase 3
7,297
Aachen, Bad Krozingen, Bad Oeynhausen, Berlin, Bremen, Cologne, Dresden, Essen
2022-12-14
Active, closed
A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer
NCT05488314Carcinoma, Non-Small-Cell Lung
DrugsCapmatinib·Amivantamab
Janssen Research & Development, LLC
Phase 1/2
57
Berlin, Chemnitz, Cologne, Dresden, Essen, Münster
2022-12-13
Active, closed
A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma
NCT05529316Advanced Melanoma
DrugsBalstilimab·Botensilimab
Agenus Inc.
Phase 2
150
Essen, Hamburg, Heidelberg, Kiel, Mainz, München, Tübingen, Würzburg
2022-12-12
Active, closed
SerUM Markers in MERkel Cell Carcinoma Patients: a Longitudinal moniTorIng Study for optiMization of European Guidelines
NCT04705389Merkel Cell Carcinoma
University Hospital, Tours
Not applicable
35
Essen
2022-12-05
Active, closed
A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
NCT05600777Cough, Refractory Chronic Cough
DrugCamlipixant
Bellus Health Inc. - a GSK company
Phase 3
997
Berlin, Bochum, Darmstadt, Dresden, Essen, Frankfurt, Frankfurt am Main, Geesthacht
2022-12-05
Active, closed
A Study to Evaluate Safety and Efficacy of Subcutaneous Administration of Anakinra in Patients With CF
NCT03925194Cystic Fibrosis, 10011762
DrugAnakinra
Heidelberg University
Phase 2
52
Heidelberg, Essen, Berlin
2022-12-01
Recruiting
HRS-AKI Treatment With TIPS in Patients With Cirrhosis
NCT05346393Cirrhosis, Liver, Hepatorenal Syndrome, Acute Kidney Injury, Ascites Hepatic
Jena University Hospital
Not applicable
124
Aachen, Berlin, Dresden, Essen, Freiburg im Breisgau, Halle, Hamburg, Hanover
2022-11-29
Active, closed
Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del
NCT05331183Cystic Fibrosis
DrugsELX/TEZ/IVA·Ivacaftor·Elexacaftor/Tezacaftor/Ivacaftor
Vertex Pharmaceuticals Incorporated
Phase 3
297
Berlin, Cologne, Essen, Frankfurt, Giessen, Halle, Hanover, Jena
2022-11-23
Recruiting
A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria
NCT05457283Chronic Kidney Disease, Proteinuria, Children
DrugFinerenone
Bayer
Phase 3
100
Heidelberg, Hanover, Bonn, Essen, Münster, Berlin, Hamburg
2022-11-08
Active, closed
A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy
NCT05444257Cystic Fibrosis
DrugVNZ/TEZ/D-IVA
Vertex Pharmaceuticals Incorporated
Phase 3
822
Berlin, Erlangen, Essen, Frankfurt, Giessen, Hanover, Jena, Mainz
2022-11-08
Active, closed
A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight
NCT05567796Obesity
DrugsCagrilintide·Semaglutide
Novo Nordisk A/S
Phase 3
3,400
Bad Mergentheim, Elsterwerda, Essen, Hamburg, Leipzig, Münster, Stuttgart, Wangen
2022-11-01
Active, closed
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
NCT05544929Carcinoma, Non-Small-Cell Lung, Cutaneous Melanoma, Carcinoma, Renal Cell, Carcinoma, Ovarian Epithelial
DrugsKeytruda·Pembrolizumab
Novartis Pharmaceuticals
Phase 1
126
Dresden, Essen
2022-10-26
Recruiting
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
NCT05552222Multiple Myeloma
DrugsTalquetamab·Teclistamab·Daratumumab·Lenalidomide
Janssen Research & Development, LLC
Phase 3
1,590
Berlin, Essen, Halle, Hamburg, Nuremberg, Tübingen, Würzburg
2022-10-25
Active, closed
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma
NCT05259839Relapsed/Refractory Multiple Myeloma
DrugsEtentamig·Pomalidomide·Daratumumab·Lenalidomide
AbbVie
Phase 1
283
Tübingen, Regensburg, Würzburg, Essen, Hamburg
2022-10-20
Active, closed
A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer
NCT05565378Lung Cancer, Non-Small Cell
DrugsNelistotug·Belrestotug·Dostarlimab·Pembrolizumab
GlaxoSmithKline
Phase 2
351
Berlin, Essen, Großhansdorf, Heidelberg, Jena
2022-10-14
Active, closed
A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer
NCT05587296Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer, Hot Flashes
Bayer
Phase 3
474
Mannheim, Tübingen, Frankfurt am Main, Hanover, Aachen, Bergisch Gladbach, Bonn, Essen
2022-10-14
Active, closed
Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer
NCT05502237Non-small Cell Lung Cancer
DrugsDomvanalimab·Zimberelimab·Nab-paclitaxel·Pemetrexed
Gilead Sciences
Phase 3
1,021
Cologne, Essen, Großhansdorf, Halle, Hamburg, Hemer, Karlsruhe, Lübeck
2022-10-12
Active, closed
A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
NCT05556512Obesity, Overweight
DrugTirzepatide
Eli Lilly and Company
Phase 3
15,374
Bad Homburg, Bad Oeynhausen, Berlin, Dresden, Essen, Frankfurt, Freiburg im Breisgau, Hamburg
2022-10-11
Active, closed
A Study to Learn About the Safety of BIIB115 Injections and How BIIB115 is Processed in the Bodies of Healthy Adult Male Volunteers and of Pediatric Participants With Spinal Muscular Atrophy Who Previously Took Onasemnogene Abeparvovec
NCT05575011Healthy Volunteer, Muscular Atrophy, Spinal
DrugSalanersen
Biogen
Phase 1
62
Essen, Freiburg im Breisgau, Heidelberg
2022-10-10
Recruiting
Intracoronary Stenting and Restenosis - Randomized Trial of Drug-eluting Stent Implantation or Drug-coated Balloon Angioplasty According to Neointima Morphology in Drug-eluting Stent Restenosis 5
NCT05544864Coronary Artery Disease, Restenoses, Coronary
Deutsches Herzzentrum Muenchen
Not applicable
376
Frankfurt am Main, Essen, Hamburg, Munich
2022-09-28
Active, closed
CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma
NCT05440786Sarcoma, Ewing, Neoplasm Metastasis
DrugsAbemaciclib·Temozolomide·Irinotecan
Eli Lilly and Company
Phase 2
46
Freiburg im Breisgau, Essen, Berlin
2022-09-20
Recruiting
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
NCT05489211Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer, Ovarian Cancer
DrugsPrednisone/Prednisolone·Volrustomig·Rilvegostomig·Datopotamab deruxtecan
AstraZeneca
Phase 2
454
Berlin, Essen, Hanover, München, Regensburg
2022-09-06
By invitation
Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease
NCT04905693Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, Progressive Pulmonary Fibrosis
DrugTreprostinil
United Therapeutics
Phase 3
1,850
Löwenstein, München, Rosenheim, Essen, Coswig, Bad Berka
2022-09-06
Recruiting
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
NCT05548296Endometrial Adenocarcinoma
DrugGemcitabine
Acrivon Therapeutics
Phase 2
350
Essen, Münster, Ulm
2022-08-29
Active, closed
First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)
NCT05361395Extensive Stage Small Cell Lung Cancer
DrugsTarlatamab·Tecentriq·Etoposide·Atezolizumab
Amgen
Phase 1
184
Dresden, Essen, Freiburg im Breisgau
2022-08-24
By invitation
Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis
NCT05374590Generalized Myasthenia Gravis, gMG
DrugsEfgartigimod PH20·Efgartigimod
argenx
Phase 2/3
12
Essen
2022-08-18
Active, closed
A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)
NCT05327530Locally Advanced or Metastatic Urothelial Carcinoma
DrugsAvelumab·Sacituzumab Govitecan
EMD Serono Research & Development Institute, Inc.
Phase 2
256
Muenchen, Halle, Essen, Frankfurt, Mönchengladbach, Münster, Tübingen
2022-08-17
Recruiting
Cardiac Amyloid Deposits and Heart Dysfunction in Alzheimer's Disease
NCT07154394Dementia, Alzheimer Type, Mild Cognitive Impairment, Cardiac Amyloidosis
University Hospital, Essen
Observational
15
Essen
2022-08-15
Active, closed
A Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older Adults
NCT05371080Herpes Zoster
GlaxoSmithKline
Phase 3
3,038
Wangen, Weinheim, Rednitzhembach, Wallerfing, Flörsheim, Cologne, Essen, Goch
2022-08-10
Active, closed
First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors
NCT05489237Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumor (GIST), Digestive System Disease, Gastrointestinal Diseases
DrugIDRX-42
IDRX, Inc., a wholly owned subsidiary of GSK, LLC
Phase 1
276
Berlin, Essen
2022-08-03
Active, closed
A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)
NCT05306340Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
DrugsGiredestrant·Tamoxifen·Exemestane·Everolimus
Genentech, Inc.
Phase 3
373
Bottrop, Erlangen, Essen, Heidelberg, Mainz
2022-08-03
Active, closed
A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes
NCT05433584Type 2 Diabetes
DrugTirzepatide
Eli Lilly and Company
Phase 4
780
Frankfurt am Main, Bochum, Essen, Saint Ingbert, Pirna, Oldenburg in Holstein, Bad Mergentheim, Gelnhausen
2022-08-01
Active, closed
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT05382286Triple Negative Breast Cancer, PD-L1 Positive
DrugsAbraxane·Sacituzumab Govitecan·Taxol·Nab-paclitaxel
Gilead Sciences
Phase 3
443
Berlin, Bonn, Bottrop, Cologne, Erlangen, Essen, Freiburg im Breisgau, Hamburg
2022-07-25
Active, closed
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
NCT05242471Crohn's Disease
DrugsJNJ-78934804·Golimumab·Guselkumab
Janssen Research & Development, LLC
Phase 2
703
Berlin, Cologne, Dachau, Dresden, Duisburg, Erlangen, Essen, Frankfurt
2022-07-22
Active, closed
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT05382299Triple Negative Breast Cancer, PD-L1 Negative
DrugsAbraxane·Sacituzumab Govitecan·Nab-paclitaxel·Gemcitabine
Gilead Sciences
Phase 3
623
Berlin, Bonn, Cologne, Essen, Hamburg, Heidelberg, Lübeck, Mannheim
2022-07-20
Recruiting
Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
NCT05413850Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, mCRPC, Urogenital Neoplasms
Blue Earth Therapeutics Ltd
Phase 1/2
82
Aachen, Augsburg, Essen, Munich
2022-07-20
Active, closed
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)
NCT05296798Locally Advanced or Metastatic Breast Cancer
DrugsPhesgo·Giredestrant·Docetaxel·Paclitaxel
Hoffmann-La Roche
Phase 3
922
Bad Nauheim, Bamberg, Essen, Freiburg im Breisgau, Heidelberg, Hildesheim, Homburg/Saar, Langen
2022-07-18
Active, closed
A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab
NCT05142696Extensive Stage Small Cell Lung Cancer
Drugs[177Lu]Lu-DOTA-TATE·[68Ga]Ga-DOTA-TATE·Lutathera·Atezolizumab
Novartis Pharmaceuticals
Phase 1/2
55
Essen
2022-07-13
Active, closed
HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy
NCT05338970Nonsquamous Non-small Cell Lung Cancer, EGFR L858R, EGFR Exon 19 Deletion
DrugPatritumab deruxtecan
Daiichi Sankyo
Phase 3
586
Essen, Esslingen am Neckar, Frankfurt am Main, Gauting, Giessen, Großhansdorf, Heidelberg, Immenhausen
2022-07-08
Recruiting
Early Stage Follicular LymphOma and RadioTherapy PLUS Anti-CD20 Antibody
NCT05045664Early Stage Follicular Lymphoma WHO Grade 1/2 or 3a
Heidelberg University
Phase 3
100
Berlin, Essen, Göttingen, Heidelberg, Mönchengladbach, Munich, Regensburg, Rostock
2022-07-06
Active, closed
A Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Participants With Spinal Muscular Atrophy
NCT05337553Spinal Muscular Atrophy, Neuromuscular Diseases, SMA
DrugTaldefgrobep alfa
Biohaven Pharmaceuticals, Inc.
Phase 3
269
Essen, Freiburg im Breisgau, Munich
2022-07-06
Active, closed
A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas
NCT05415072Metastatic Uveal Melanoma
Novartis Pharmaceuticals
Phase 1/2
66
Essen, Heidelberg
2022-07-04
Recruiting
CytOSorb TreatMent Of Critically Ill PatientS Registry
NCT05146336Septic Shock, Acute Respiratory Distress Syndrome, Trauma, Rhabdomyolysis
CytoSorbents, Inc
Observational
3,000
Aachen, Bad Oeynhausen, Bochum, Essen, Göttingen, Herford, Jena, Kassel
2022-06-22
Active, closed
Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age
NCT05422222Cystic Fibrosis
DrugVNZ/TEZ/D-IVA
Vertex Pharmaceuticals Incorporated
Phase 3
210
Berlin, Essen, Hanover
2022-06-21
Active, closed
BIVV020 (SAR445088) in Prevention and Treatment of Antibody-mediated Rejection (AMR)
NCT05156710Transplant Rejection
DrugsAntithymocyte globulin·Riliprubart·Immunoglobulin·IVIG
Sanofi
Phase 2
48
Berlin, Essen, Munich
2022-06-09
Recruiting
Optimizing Quality of Life by Improved Patient Expectation Following Atrial Fibrillation Catheter Ablation
NCT05557526Atrial Fibrillation
Evangelical Hospital Düsseldorf
Not applicable
60
Düsseldorf, Essen
2022-06-09
Recruiting
The Head and Neck Registry of the European Reference Network on Rare Adult Solid Cancers
NCT05483374Head and Neck Cancer, Nasopharynx Cancer, Nasal Cavity and Paranasal Sinus Cancer, Salivary Gland Cancer
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Observational
13,600
Essen
2022-05-31
Recruiting
SELUTION4BTK Trial
NCT05055297Peripheral Arterial Disease, Chronic Limb-Threatening Ischemia Nos of Native Arteries of Extremities
M.A. Med Alliance S.A.
Not applicable
376
Arnsberg, Bad Krozingen, Buchholz, Coburg, Essen, Tübingen
2022-05-19
Active, closed
IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)
NCT05155254Metastatic Melanoma, Unresectable Melanoma
DrugsIO102-IO103·Pembrolizumab
IO Biotech
Phase 3
407
Augsburg, Berlin, Bochum, Erlangen, Essen, Frankfurt, Halle, Hamburg
2022-05-17
Recruiting
WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC
NCT04644289Epithelial Ovarian Cancer
DrugsOlaparib·Durvalumab
AGO Research GmbH
Phase 2
60
Mannheim, München, Hamburg, Essen, Dresden, Berlin
2022-05-05
Rows per page Showing 401–500 of 760
Previous 3 4 5 6 7 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a German investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 30 September 2026. https://priyalifescience.com/clinical-trials-germany/city/essen?page=5

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Germany and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,051 studies in total at the last sync on 26 Sep 2026, 19:51 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 760 of those studies with a site in Essen.

How many clinical trials are recruiting in Essen?

375 of the 760 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:51 UTC sync. A further 15 have not yet opened recruitment, 361 are active but closed to new participants, and 9 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.